Abionyx Pharma SA (ABNX) - Total Liabilities

Latest as of June 2025: €7.56 Million EUR ≈ $8.84 Million USD

Based on the latest financial reports, Abionyx Pharma SA (ABNX) has total liabilities worth €7.56 Million EUR (≈ $8.84 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Abionyx Pharma SA annual equity growth to track the company's year-over-year net asset growth rate.

Abionyx Pharma SA - Total Liabilities Trend (2013–2024)

This chart illustrates how Abionyx Pharma SA's total liabilities have evolved over time, based on quarterly financial data. See Abionyx Pharma SA (ABNX) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Abionyx Pharma SA Competitors by Total Liabilities

The table below lists competitors of Abionyx Pharma SA ranked by their total liabilities.

Company	Country	Total Liabilities
Starry Sea Acquisition Corp Ordinary Shares NASDAQ:SSEA	USA	$27.23K
Atlas Lithium Corporation Common Stock NASDAQ:ATLX	USA	$34.72 Million
Mordechai Aviv Taasiot Beniyah 1973 Ltd TA:AVIV	Israel	ILA701.99 Million
Games Workshop Group PLC LSE:GAW	UK	GBX102.20 Million
Subex Limited NSE:SUBEXLTD	India	Rs1.95 Billion
Country View Bhd KLSE:5049	Malaysia	RM212.64 Million
Grimoldi SA BA:GRIM	Argentina	AR$80.87 Billion
Symphony Communication Public Company Limited BK:SYMC	Thailand	฿1.66 Billion

Liability Composition Analysis (2013–2024)

This chart breaks down Abionyx Pharma SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Abionyx Pharma SA worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.40	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.40	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.58	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Abionyx Pharma SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Abionyx Pharma SA (2013–2024)

The table below shows the annual total liabilities of Abionyx Pharma SA from 2013 to 2024.

Year	Total Liabilities	Change
2024-12-31	€6.03 Million ≈ $7.05 Million	-12.82%
2023-12-31	€6.91 Million ≈ $8.08 Million	-20.13%
2022-12-31	€8.65 Million ≈ $10.12 Million	-22.42%
2021-12-31	€11.15 Million ≈ $13.04 Million	+204.86%
2020-12-31	€3.66 Million ≈ $4.28 Million	+2.12%
2019-12-31	€3.58 Million ≈ $4.19 Million	-61.46%
2018-12-31	€9.30 Million ≈ $10.87 Million	-1.18%
2017-12-31	€9.41 Million ≈ $11.00 Million	-34.91%
2016-12-31	€14.46 Million ≈ $16.90 Million	+11.98%
2015-12-31	€12.91 Million ≈ $15.09 Million	+19.24%
2014-12-31	€10.82 Million ≈ $12.66 Million	+39.44%
2013-12-31	€7.76 Million ≈ $9.08 Million	--

About Abionyx Pharma SA

PA:ABNX France Biotechnology

Market Cap

$77.13 Million

€65.97 Million EUR

Market Cap Rank

#20157 Global

#313 in France

Share Price

€1.87

Change (1 day)

+0.75%

52-Week Range

€1.59 - €5.00

All Time High

€12.79